+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Blood Plasma Derivatives Market by Product Type, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 258 Pages
  • February 2022
  • Region: Global
  • Allied Market Research
  • ID: 5578211
The global blood plasma derivatives market was valued at $ 36,471.9 million in 2020, and is projected to reach $ 89,767 million by 2030, registering a CAGR of 9.4% from 2021 to 2030.

Blood plasma is liquid component of blood where the blood cells are suspended. It contains dissolved proteins (albumins, globulins, and fibrinogen), clotting factors, hormones, and electrolytes. Plasma maintains the blood pressure and helps in exchange of important minerals such as sodium and potassium to maintain the pH balance in the body. Plasma derivatives are products that are manufactured from human plasma by plasma fractionation techniques. These derivatives include albumin, factor VIII & IX, anti-inhibitor coagulation complex (AICC), and immunoglobulins, including Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III.

The major factor that contributes toward the growth of the blood plasma derivatives market is increase in prevalence of life-threatening diseases such as immunodeficiency disorders and hemophilia. Moreover, other factors that boost the market growth include increase in awareness for blood & plasma donation, rise in geriatric population, and high adoption of blood plasma derivatives products. However, high cost of treatment and risks of side effects associated with the use of plasma derivatives hamper the market growth. Conversely, development of enhanced methods for preservation of plasma derivatives along with advanced procedures for fractionation and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market.

The blood plasma derivatives market is segmented on the basis of type, application, end user, and region. Based on type, the market is fragmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The applications covered in the study include hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand's Disease (vWD), and other applications. By end user, the market is classified into hospitals, clinics, and other end users. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of the blood plasma derivative market size along with the current trends and future estimations to elucidate the imminent investment pockets
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global blood plasma derivative market

KEY MARKET SEGMENTS


By Type

  • Albumin
  • Factor VIII
  • Factor IX
  • Immunoglobulin
  • Hyperimmune Globulin
  • Others

By Application

  • Hemophilia
  • Hypogammaglobulinemia
  • Immunodeficiency Diseases
  • Von Willebrand'S Disease
  • Other Application

By End User

  • Hospitals
  • Clinics
  • Other End Users

By Region

  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Bayer AG
  • Biotest AG
  • CSL limited
  • Fusion Health Care Pvt Ltd
  • Grifols ,SA
  • Kedrion Biopharma ,Inc
  • LFB SA
  • Octapharma AG
  • Sanofi
  • Takeda
Frequently Asked Questions about the Global Blood Plasma Derivatives Market

What is the estimated value of the Global Blood Plasma Derivatives Market?

The Global Blood Plasma Derivatives Market was estimated to be valued at $36471.9 million in 2020.

What is the growth rate of the Global Blood Plasma Derivatives Market?

The growth rate of the Global Blood Plasma Derivatives Market is 9.4%, with an estimated value of $89767 million by 2030.

What is the forecasted size of the Global Blood Plasma Derivatives Market?

The Global Blood Plasma Derivatives Market is estimated to be worth $89767 million by 2030.

Who are the key companies in the Global Blood Plasma Derivatives Market?

Key companies in the Global Blood Plasma Derivatives Market include Bayer AG, Biotest AG, CSL limited, Fusion Health Care Pvt. Ltd, Grifols, Kedrion Biopharma ,Inc., LFB S.A, Octapharma AG, Sanofi and Takeda..

Table of Contents

Chapter 1: Introduction
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
Chapter 2: Executive Summary
2.1. Cxo Perspective
Chapter 3: Market Landscape
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power Among Buyers
3.4. Market Share Analysis/Top Player Positioning
3.4.1. Market Share Analysis/Top Player Positioning 2020
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. Covid-19 Impact Analysis
Chapter 4: Blood Plasma Derivatives Market, by Type
4.1. Market Overview
4.1.1Market Size and Forecast, by Type
4.2. Albumin
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Share Analysis, by Country
4.3. Factor Viii
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Share Analysis, by Country
4.4. Factor Ix
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Share Analysis, by Country
4.5. Immunoglobulin
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, by Region
4.5.3. Market Share Analysis, by Country
4.6. Hyperimmune Globulin
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, by Region
4.6.3. Market Share Analysis, by Country
4.7. Others
4.7.1. Key Market Trends, Growth Factors and Opportunities
4.7.2. Market Size and Forecast, by Region
4.7.3. Market Share Analysis, by Country
Chapter 5: Blood Plasma Derivatives Market, by Application
5.1. Market Overview
5.1.1Market Size and Forecast, by Application
5.2. Hemophilia
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, by Region
5.2.3. Market Share Analysis, by Country
5.3. Hypogammaglobulinemia
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, by Region
5.3.3. Market Share Analysis, by Country
5.4. Immunodeficiency Diseases
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, by Region
5.4.3. Market Share Analysis, by Country
5.5. Von Willebrand's Disease
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, by Region
5.5.3. Market Share Analysis, by Country
5.6. Other Application
5.6.1. Key Market Trends, Growth Factors and Opportunities
5.6.2. Market Size and Forecast, by Region
5.6.3. Market Share Analysis, by Country
Chapter 6: Blood Plasma Derivatives Market, by End-user
6.1. Market Overview
6.1.1Market Size and Forecast, by End-user
6.2. Hospitals
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, by Region
6.2.3. Market Share Analysis, by Country
6.3. Clinics
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, by Region
6.3.3. Market Share Analysis, by Country
6.4. Other End-users
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, by Region
6.4.3. Market Share Analysis, by Country
Chapter 7: Blood Plasma Derivatives Market, by Region
7.1. Market Overview
7.1.1Market Size and Forecast, by Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, by Type
7.2.3. Market Size and Forecast, by Application
7.2.4. Market Size and Forecast, by End-user
7.2.5. Market Size and Forecast, by Country
7.2.6. United States Blood Plasma Derivatives Market
7.2.6.1. Market Size and Forecast, by Type
7.2.6.2. Market Size and Forecast, by Application
7.2.6.3. Market Size and Forecast, by End-user
7.2.7. Canada Blood Plasma Derivatives Market
7.2.7.1. Market Size and Forecast, by Type
7.2.7.2. Market Size and Forecast, by Application
7.2.7.3. Market Size and Forecast, by End-user
7.2.8. Mexico Blood Plasma Derivatives Market
7.2.8.1. Market Size and Forecast, by Type
7.2.8.2. Market Size and Forecast, by Application
7.2.8.3. Market Size and Forecast, by End-user
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, by Type
7.3.3. Market Size and Forecast, by Application
7.3.4. Market Size and Forecast, by End-user
7.3.5. Market Size and Forecast, by Country
7.3.6. Germany Blood Plasma Derivatives Market
7.3.6.1. Market Size and Forecast, by Type
7.3.6.2. Market Size and Forecast, by Application
7.3.6.3. Market Size and Forecast, by End-user
7.3.7. France Blood Plasma Derivatives Market
7.3.7.1. Market Size and Forecast, by Type
7.3.7.2. Market Size and Forecast, by Application
7.3.7.3. Market Size and Forecast, by End-user
7.3.8. U. K Blood Plasma Derivatives Market
7.3.8.1. Market Size and Forecast, by Type
7.3.8.2. Market Size and Forecast, by Application
7.3.8.3. Market Size and Forecast, by End-user
7.3.9. Italy Blood Plasma Derivatives Market
7.3.9.1. Market Size and Forecast, by Type
7.3.9.2. Market Size and Forecast, by Application
7.3.9.3. Market Size and Forecast, by End-user
7.3.10. Spain Blood Plasma Derivatives Market
7.3.10.1. Market Size and Forecast, by Type
7.3.10.2. Market Size and Forecast, by Application
7.3.10.3. Market Size and Forecast, by End-user
7.3.11. Rest of Europe Blood Plasma Derivatives Market
7.3.11.1. Market Size and Forecast, by Type
7.3.11.2. Market Size and Forecast, by Application
7.3.11.3. Market Size and Forecast, by End-user
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, by Type
7.4.3. Market Size and Forecast, by Application
7.4.4. Market Size and Forecast, by End-user
7.4.5. Market Size and Forecast, by Country
7.4.6. Japan Blood Plasma Derivatives Market
7.4.6.1. Market Size and Forecast, by Type
7.4.6.2. Market Size and Forecast, by Application
7.4.6.3. Market Size and Forecast, by End-user
7.4.7. China Blood Plasma Derivatives Market
7.4.7.1. Market Size and Forecast, by Type
7.4.7.2. Market Size and Forecast, by Application
7.4.7.3. Market Size and Forecast, by End-user
7.4.8. India Blood Plasma Derivatives Market
7.4.8.1. Market Size and Forecast, by Type
7.4.8.2. Market Size and Forecast, by Application
7.4.8.3. Market Size and Forecast, by End-user
7.4.9. Australia Blood Plasma Derivatives Market
7.4.9.1. Market Size and Forecast, by Type
7.4.9.2. Market Size and Forecast, by Application
7.4.9.3. Market Size and Forecast, by End-user
7.4.10. South Korea Blood Plasma Derivatives Market
7.4.10.1. Market Size and Forecast, by Type
7.4.10.2. Market Size and Forecast, by Application
7.4.10.3. Market Size and Forecast, by End-user
7.4.11. Rest of Asia-Pacific Blood Plasma Derivatives Market
7.4.11.1. Market Size and Forecast, by Type
7.4.11.2. Market Size and Forecast, by Application
7.4.11.3. Market Size and Forecast, by End-user
7.5. Lamea
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, by Type
7.5.3. Market Size and Forecast, by Application
7.5.4. Market Size and Forecast, by End-user
7.5.5. Market Size and Forecast, by Country
7.5.6. Brazil Blood Plasma Derivatives Market
7.5.6.1. Market Size and Forecast, by Type
7.5.6.2. Market Size and Forecast, by Application
7.5.6.3. Market Size and Forecast, by End-user
7.5.7. South Africa, Blood Plasma Derivatives Market
7.5.7.1. Market Size and Forecast, by Type
7.5.7.2. Market Size and Forecast, by Application
7.5.7.3. Market Size and Forecast, by End-user
7.5.8. Saudi Arabia Blood Plasma Derivatives Market
7.5.8.1. Market Size and Forecast, by Type
7.5.8.2. Market Size and Forecast, by Application
7.5.8.3. Market Size and Forecast, by End-user
7.5.9. Rest of LAMEA Blood Plasma Derivatives Market
7.5.9.1. Market Size and Forecast, by Type
7.5.9.2. Market Size and Forecast, by Application
7.5.9.3. Market Size and Forecast, by End-user
Chapter 8: Company Profiles
8.1. Bayer AG
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Biotest AG
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Csl Limited
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Fusion Health Care Pvt. Ltd
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Kedrion Biopharma ,Inc.
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Lfb S. A
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Octapharma AG
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Takeda
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Sanofi
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Grifols
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
List of Tables
Table 1. Global Blood Plasma Derivatives Market, by Type, 2020-2030 ($Million)
Table 2. Global Blood Plasma Derivatives Market for Albumin, by Region, 2020-2030 ($Million)
Table 3. Global Blood Plasma Derivatives Market for Factor Viii, by Region, 2020-2030 ($Million)
Table 4. Global Blood Plasma Derivatives Market for Factor Ix, by Region, 2020-2030 ($Million)
Table 5. Global Blood Plasma Derivatives Market for Immunoglobulin, by Region, 2020-2030 ($Million)
Table 6. Global Blood Plasma Derivatives Market for Hyperimmune Globulin, by Region, 2020-2030 ($Million)
Table 7. Global Blood Plasma Derivatives Market for Others, by Region, 2020-2030 ($Million)
Table 8. Global Blood Plasma Derivatives Market, by Application, 2020-2030 ($Million)
Table 9. Global Blood Plasma Derivatives Market for Hemophilia, by Region, 2020-2030 ($Million)
Table 10. Global Blood Plasma Derivatives Market for Hypogammaglobulinemia, by Region, 2020-2030 ($Million)
Table 11. Global Blood Plasma Derivatives Market for Immunodeficiency Diseases, by Region, 2020-2030 ($Million)
Table 12. Global Blood Plasma Derivatives Market for Von Willebrand's Disease, by Region, 2020-2030 ($Million)
Table 13. Global Blood Plasma Derivatives Market for Other Application, by Region, 2020-2030 ($Million)
Table 14. Global Blood Plasma Derivatives Market, by End-user, 2020-2030 ($Million)
Table 15. Global Blood Plasma Derivatives Market for Hospitals, by Region, 2020-2030 ($Million)
Table 16. Global Blood Plasma Derivatives Market for Clinics, by Region, 2020-2030 ($Million)
Table 17. Global Blood Plasma Derivatives Market for Other End-users, by Region, 2020-2030 ($Million)
Table 18. Global Blood Plasma Derivatives Market, by Region, 2020-2030 ($Million)
Table 19. North America Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 20. North America Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 21. North America Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 22. United States Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 23. United States Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 24. United States Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 25. Canada Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 26. Canada Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 27. Canada Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 28. Mexico Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 29. Mexico Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 30. Mexico Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 31. Europe Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 32. Europe Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 33. Europe Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 34. Germany Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 35. Germany Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 36. Germany Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 37. France Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 38. France Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 39. France Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 40. United Kingdom Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 41. United Kingdom Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 42. United Kingdom Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 43. Italy Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 44. Italy Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 45. Italy Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 46. Spain Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 47. Spain Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 48. Spain Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 49. Rest of Europe Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 50. Rest of Europe Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 51. Rest of Europe Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 52. Asia-Pacific Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 53. Asia-Pacific Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 54. Asia-Pacific Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 55. Japan Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 56. Japan Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 57. Japan Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 58. China Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 59. China Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 60. China Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 61. India Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 62. India Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 63. India Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 64. Australia Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 65. Australia Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 66. Australia Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 67. South Korea Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 68. South Korea Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 69. South Korea Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 70. Rest of Asia-Pacific Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 71. Rest of Asia-Pacific Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 72. Rest of Asia-Pacific Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 73. LAMEA Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 74. LAMEA Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 75. LAMEA Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 76. Brazil Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 77. Brazil Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 78. Brazil Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 79. South Africa, Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 80. South Africa, Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 81. South Africa, Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 82. Saudi Arabia Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 83. Saudi Arabia Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 84. Saudi Arabia Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 85. Rest of LAMEA Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 86. Rest of LAMEA Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 87. Rest of LAMEA Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 88. Bayer Ag: Key Executives
Table 89. Bayer Ag: Company Snapshot
Table 90. Bayer Ag: Operating Segments
Table 91. Bayer Ag: Product Portfolio
Table 92. Bayer Ag: Key Strategic Moves and Developments
Table 93. Biotest Ag: Key Executives
Table 94. Biotest Ag: Company Snapshot
Table 95. Biotest Ag: Operating Segments
Table 96. Biotest Ag: Product Portfolio
Table 97. Biotest Ag: Key Strategic Moves and Developments
Table 98. Csl Limited: Key Executives
Table 99. Csl Limited: Company Snapshot
Table 100. Csl Limited: Operating Segments
Table 101. Csl Limited: Product Portfolio
Table 102. Csl Limited: Key Strategic Moves and Developments
Table 103. Fusion Health Care Pvt. Ltd: Key Executives
Table 104. Fusion Health Care Pvt. Ltd: Company Snapshot
Table 105. Fusion Health Care Pvt. Ltd: Operating Segments
Table 106. Fusion Health Care Pvt. Ltd: Product Portfolio
Table 107. Fusion Health Care Pvt. Ltd: Key Strategic Moves and Developments
Table 108. Kedrion Biopharma ,Inc. : Key Executives
Table 109. Kedrion Biopharma ,Inc. : Company Snapshot
Table 110. Kedrion Biopharma ,Inc. : Operating Segments
Table 111. Kedrion Biopharma ,Inc. : Product Portfolio
Table 112. Kedrion Biopharma ,Inc. : Key Strategic Moves and Developments
Table 113. Lfb S. A: Key Executives
Table 114. Lfb S. A: Company Snapshot
Table 115. Lfb S. A: Operating Segments
Table 116. Lfb S. A: Product Portfolio
Table 117. Lfb S. A: Key Strategic Moves and Developments
Table 118. Octapharma Ag: Key Executives
Table 119. Octapharma Ag: Company Snapshot
Table 120. Octapharma Ag: Operating Segments
Table 121. Octapharma Ag: Product Portfolio
Table 122. Octapharma Ag: Key Strategic Moves and Developments
Table 123. Takeda: Key Executives
Table 124. Takeda: Company Snapshot
Table 125. Takeda: Operating Segments
Table 126. Takeda: Product Portfolio
Table 127. Takeda: Key Strategic Moves and Developments
Table 128. Sanofi: Key Executives
Table 129. Sanofi: Company Snapshot
Table 130. Sanofi: Operating Segments
Table 131. Sanofi: Product Portfolio
Table 132. Sanofi: Key Strategic Moves and Developments
Table 133. Grifols: Key Executives
Table 134. Grifols: Company Snapshot
Table 135. Grifols: Operating Segments
Table 136. Grifols: Product Portfolio
Table 137. Grifols: Key Strategic Moves and Developments
List of Figures
Figure 1. Global Blood Plasma Derivatives Market Segmentation
Figure 2. Global Blood Plasma Derivatives Market
Figure 3. Segmentation Blood Plasma Derivatives Market
Figure 4. Top Investment Pocket in Blood Plasma Derivatives Market
Figure 5. Top Winning Strategies, 2019-2021*
Figure 6. Top Winning Strategies, by Development, 2019-2021(%)
Figure 7. Top Winning Strategies, by Company, 2019-2021*
Figure 8. Moderate Bargaining Power of Buyers
Figure 9. Moderate Bargaining Power of Suppliers
Figure 10. Moderate Threat of New Entrants
Figure 11. Low Threat of Substitution
Figure 12. High Competitive Rivalry
Figure 13. Top Player Positioning, 2020
Figure 14. Market Share Analysis, 2020
Figure 15. Restraints and Drivers: Blood Plasma Derivatives Market
Figure 16. Blood Plasma Derivatives Market Segmentation, by Type
Figure 17. Blood Plasma Derivatives Market for Albumin, by Country, 2020-2030 ($ Million)
Figure 18. Blood Plasma Derivatives Market for Factor Viii, by Country, 2020-2030 ($ Million)
Figure 19. Blood Plasma Derivatives Market for Factor Ix, by Country, 2020-2030 ($ Million)
Figure 20. Blood Plasma Derivatives Market for Immunoglobulin, by Country, 2020-2030 ($ Million)
Figure 21. Blood Plasma Derivatives Market for Hyperimmune Globulin, by Country, 2020-2030 ($ Million)
Figure 22. Blood Plasma Derivatives Market for Others, by Country, 2020-2030 ($ Million)
Figure 23. Blood Plasma Derivatives Market Segmentation, by Application
Figure 24. Blood Plasma Derivatives Market for Hemophilia, by Country, 2020-2030 ($ Million)
Figure 25. Blood Plasma Derivatives Market for Hypogammaglobulinemia, by Country, 2020-2030 ($ Million)
Figure 26. Blood Plasma Derivatives Market for Immunodeficiency Diseases, by Country, 2020-2030 ($ Million)
Figure 27. Blood Plasma Derivatives Market for Von Willebrand's Disease, by Country, 2020-2030 ($ Million)
Figure 28. Blood Plasma Derivatives Market for Other Application, by Country, 2020-2030 ($ Million)
Figure 29. Blood Plasma Derivatives Market Segmentation, by End-user
Figure 30. Blood Plasma Derivatives Market for Hospitals, by Country, 2020-2030 ($ Million)
Figure 31. Blood Plasma Derivatives Market for Clinics, by Country, 2020-2030 ($ Million)
Figure 32. Blood Plasma Derivatives Market for Other End-users, by Country, 2020-2030 ($ Million)
Figure 33. Bayer Ag: Net Sales, 2018-2020 ($ Million)
Figure 34. Bayer Ag: Revenue Share, by Segment, 2020 (%)
Figure 35. Bayer Ag: Revenue Share, by Region, 2020 (%)
Figure 36. Biotest Ag: Net Sales, 2018-2020 ($ Million)
Figure 37. Biotest Ag: Revenue Share, by Segment, 2020 (%)
Figure 38. Biotest Ag: Revenue Share, by Region, 2020 (%)
Figure 39. Csl Limited: Net Sales, 2018-2020 ($ Million)
Figure 40. Csl Limited: Revenue Share, by Segment, 2020 (%)
Figure 41. Csl Limited: Revenue Share, by Region, 2020 (%)
Figure 42. Fusion Health Care Pvt. Ltd: Net Sales, 2018-2020 ($ Million)
Figure 43. Fusion Health Care Pvt. Ltd: Revenue Share, by Segment, 2020 (%)
Figure 44. Fusion Health Care Pvt. Ltd: Revenue Share, by Region, 2020 (%)
Figure 45. Kedrion Biopharma ,Inc: Net Sales, 2018-2020 ($ Million)
Figure 46. Kedrion Biopharma ,Inc: Revenue Share, by Segment, 2020 (%)
Figure 47. Kedrion Biopharma ,Inc: Revenue Share, by Region, 2020 (%)
Figure 48. Lfb S. A: Net Sales, 2018-2020 ($ Million)
Figure 49. Lfb S. A: Revenue Share, by Segment, 2020 (%)
Figure 50. Lfb S. A: Revenue Share, by Region, 2020 (%)
Figure 51. Octapharma Ag: Net Sales, 2018-2020 ($ Million)
Figure 52. Octapharma Ag: Revenue Share, by Segment, 2020 (%)
Figure 53. Octapharma Ag: Revenue Share, by Region, 2020 (%)
Figure 54. Takeda: Net Sales, 2018-2020 ($ Million)
Figure 55. Takeda: Revenue Share, by Segment, 2020 (%)
Figure 56. Takeda: Revenue Share, by Region, 2020 (%)
Figure 57. Sanofi: Net Sales, 2018-2020 ($ Million)
Figure 58. Sanofi: Revenue Share, by Segment, 2020 (%)
Figure 59. Sanofi: Revenue Share, by Region, 2020 (%)
Figure 60. Grifols: Net Sales, 2018-2020 ($ Million)
Figure 61. Grifols: Revenue Share, by Segment, 2020 (%)
Figure 62. Grifols: Revenue Share, by Region, 2020 (%)

Executive Summary

According to a new report titled, “Blood Plasma Derivatives Market by Type, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2021–2030, the global blood plasma derivatives market size was valued at $36.471 billion in 2020, and is estimated to reach $89.767 billion by 2030, growing at a CAGR of 9.4% from 2021 to 2030.

Blood plasma is clear liquid component of blood in which red blood cells, white blood cells, and platelets are suspended. It plays a vital role in maintaining proper pH balance in the body and transporting nutrients throughout the body. It is composed of more than 100 different proteins, including albumin, fibrinogen, immunoglobulins, protease inhibitors, and clotting factors. Plasma derivatives are products that are derived from blood plasma on fractionation, and are widely used to treat variety of diseases. These derivatives include albumin, factor VIII & IX, anti-inhibitor coagulation complex (AICC), immunoglobulins, including Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III concentrate.

The factors that drive the growth of the blood plasma derivatives market include increase in prevalence of life-threatening diseases such as immunodeficiency diseases & hemophilia, rise in awareness toward blood & plasma donation, and growth in adoption of blood plasma derivatives products.

Moreover, other factors that are responsible for the growth of the plasma derived derivatives are increase in awareness of blood & plasma donation, rise in geriatric population, & higher adoption of the blood plasma derivative products. Furthermore, market players are focused on manufacturing of different blood plasma derivatives product. For instance, in April 2020, Biotest, a pharmaceutical company, announced the launch of a life saving medicine, which is derived blood plasma of COVID-19 patient. Moreover, surge in prevalence of geriatric population, who are more vulnerable to chronic disease escalate the blood plasma derivatives market growth.

In addition, rise in disposable income and development of the pharmaceutical sector for manufacturing of plasma derived products is anticipated to drive growth of the market. In addition, expansion of many clinical studies on various types of products to evaluate their safety and efficacy propels the growth of the market. For instance, in February 2022, the U.S Food and Drug Administration (FDA), announced clinical research activities in order to enhance the safety of blood plasma derive product, such as protein used to treat immune system disorder and clotting disorder.

Rise in number of approval for plasma derived products and increase in number of pharmaceutical manufacturing companies are the key factors that further boost growth of the blood plasma derivatives market. However, high cost of plasma derivative-based treatment and risk of side effects associated after using plasma derivatives impede the market growth. Conversely, the development of superior methods for preservation of plasma derivatives along with advanced processes for fractionation and presence of untapped market in emerging economies are expected to provide lucrative growth opportunities for the market.

The blood plasma derivatives market is segmented into type, application, end user, and region. On the basis of type, the market is segregated into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The immunoglobulin segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to rise in R&D activities related to manufacturing of plasma derived products in the pharmaceutical sector and increase in prevalence of immune disease.

Depending on application, the blood plasma derivatives market is classified into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand's Disease (vWD), and other applications. The immunodeficiency diseases segment is expected to lead during the forecast period, owing to increase in prevalence of immune diseases and development of advanced drugs by the pharmaceutical industry. By end user, the market is categorized into hospital, clinic, and other end users. The hospital segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to surge in number of hospital, and initiatives taken by governments & private organizations to develop healthcare sector.

The COVID-19 outbreak is anticipated to have a positive impact on growth of the global plasma derivatives market. The COVID-19 pandemic has stressed healthcare systems in the world. Meanwhile, in August 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for convalescent plasma for the treatment of hospitalized patients with COVID-19. The antibodies or plasma are collected from donors who have recovered from COVID-19. It may contain antibodies to SARS-CoV-2, which help suppress viral replication. Thus, upsurge in demand for plasma derived product for the treatment of infectious diseases positively impacted the growth of the market.

Key Findings Of The Study


  • By type, the immunodeficiency disorder was the highest contributor to the blood plasma derivatives market in 2020
  • On the basis of application, other application dominated the market in 2020, and is expected to continue this trend during the forecast period
  • Depending on end user, the hospital segment led the blood plasma derivatives market in 2020
  • Region wise, North America garnered the largest revenue share in 2020, however, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period
  • North America garnered a major share of the blood plasma derivatives market in 2020, and is expected to continue to dominate during the forecast period, owing to increase in number of approval for blood plasma derivative product and rise in number of key players to manufacture plasma derived drug. However, Asia-Pacific is expected to register highest CAGR of 110% from 2021 to 2030, owing to increase in prevalence of immune disease, rise in awareness toward plasma derivatives, and surge in healthcare expenditure

Companies Mentioned

  • Bayer AG
  • Biotest AG
  • CSL limited
  • Fusion Health Care Pvt. Ltd
  • Grifols
  • Kedrion Biopharma ,Inc.
  • LFB S.A
  • Octapharma AG
  • Sanofi
  • Takeda.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...